Trial Profile
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms AURA17
- Sponsors AstraZeneca
- 01 Dec 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.
- 07 Dec 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 27 Dec 2019 Results (n=22) of pooled analysis evaluating the effect of Osimertinib in AURA LM analysis from AURA extension, AURA2, AURA17 and AURA3 studies, published in the Journal of Thoracic Oncology.